Apogee Therapeutics (APGE) Guggenheim's Inaugural Healthcare Innovation Conference summary

Strategic focus and innovation

• Emphasis on optimized antibodies targeting validated inflammatory pathways, especially TH2, with a focus on best-in-class monotherapies and combination therapies for atopic dermatitis and respiratory diseases.

• APG777, an IL-13 antibody, is in phase II for atopic dermatitis, aiming for every 3-6 month dosing and improved efficacy over current standards.

• Combination approaches, such as APG777 with OX40L (APG990), are planned to further raise efficacy in atopic dermatitis.

• Similar strategies are being applied to respiratory indications, with expansion into asthma and COPD.

• The portfolio is designed to address derm, respiratory, and GI disorders, leveraging learnings from each indication to accelerate development.

Market opportunity and competitive landscape

• Atopic dermatitis represents the largest I&I market with low biologic penetration, offering significant growth potential.

• Payers recognize the value of innovative therapies, with the market projected to reach $50 billion annually.

• Asthma and COPD are also seen as large, underpenetrated opportunities for expansion.

• The approach aims to position new agents as first-line biologics, competing directly with established products.

Differentiation and clinical development

• APG777 offers a 75-day half-life, enabling less frequent dosing and potentially superior efficacy compared to existing IL-13 agents.

• Data suggest higher exposures may yield better efficacy, with targets set for 30-40% greater exposure in trials.

• Combination of deep IL-13 inhibition and broad OX40L targeting is hypothesized to address disease heterogeneity in atopic dermatitis.

• OX40L is favored over OX40 due to a better safety profile and comparable or superior efficacy.

• The goal is to achieve JAK-like efficacy without associated safety risks, especially for moderate to severe AD patients.